3 Paediatric Hospitals, Pathology Network and Multi-Specialty Care Stocks With a Strong Future Roadmap: Rainbow Children’s Medicare, Metropolis Healthcare and Fortis Healthcare
- October 22, 2026
- Posted by: Neeraj Pandey
- Category: Best Stocks
Rainbow Children’s Medicare, Metropolis Healthcare and Fortis Healthcare: ROE of 10.5% to 16.9% and FY22 to FY26 revenue CAGR of 7.6% to 15.2%. Prices as of 21 Oct 2026.
Quick Answer
The three paediatric care and diagnostics stocks to watch are Rainbow Children’s Medicare, Metropolis Healthcare and Fortis Healthcare. Their return on equity ranges from 10.5% to 16.9%, and their revenue compound annual growth from FY22 to FY26 ranges from 7.6% to 15.2%. Rainbow Children’s Medicare leads on both return on equity at 16.9% and revenue growth at 15.2% a year. Prices are based on the 21 October 2026 close, and this article is educational, not investment advice.
Paediatric care and diagnostics stocks let investors follow providers that treat families and test patients. Rainbow Children’s Medicare, Metropolis Healthcare and Fortis Healthcare cover paediatric and maternity hospitals, a national pathology network and multi-specialty hospitals.
This list covers three paediatric care and diagnostics stocks with complete current figures: Rainbow Children’s Medicare, Metropolis Healthcare and Fortis Healthcare. Every figure comes from the latest reported financials and the 21 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Paediatric Care and Diagnostics Stocks?
Paediatric care and diagnostics stocks are listed companies that run hospitals and diagnostic laboratories on a commercial basis. Their earnings depend on bed capacity, occupancy, test volumes and the mix of services.
Paediatric Care and Diagnostics Stocks at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Rainbow Children’s Medicare | 1,209 | 12,554 | 43.2 | 59.6 | 16.9 | 0.54 |
| Metropolis Healthcare | 533.6 | 10,780 | 53.1 | 59.6 | 12.6 | 0.15 |
| Fortis Healthcare | 729 | 55,554 | 51.9 | 59.6 | 10.5 | 0.35 |
On valuation, all three trade at a P/E below their industry P/E, which means the market is pricing them at a lower multiple than their peer group. Readers comparing paediatric care and diagnostics stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in paediatric care and diagnostics stocks can use the coming numbers to test whether growth is holding.
Why Do Paediatric Care and Diagnostics Stocks Have a Strong Roadmap in India?
Paediatric care and diagnostics stocks have a strong roadmap in India because rising incomes, insurance cover and awareness of early testing and specialised care are growing faster than the supply of organised providers.
- Specialised care. Paediatric and maternity services draw repeat patients.
- Preventive testing. More people take regular health checks.
- Capacity additions. New beds and centres widen reach in proven cities.
Why Rainbow Children’s Medicare Features Among These Paediatric Care and Diagnostics Stocks
Among the paediatric care and diagnostics stocks on this list, Rainbow Children’s Medicare operates paediatric, neonatal and maternity hospitals under the Rainbow Children’s Hospital and BirthRight by Rainbow brands, with clusters in Hyderabad, Bengaluru, Chennai and Delhi NCR.
Revenue rose from Rs 993 crore in FY22 to Rs 1,747 crore in FY26, a compound annual growth rate of 15.2%. Net profit grew from Rs 139 crore in FY22 to Rs 282 crore in FY26, which works out to a compound annual growth rate of 19.4%.
In the June 2026 quarter, revenue grew 29.4% year on year to Rs 483 crore, while net profit rose 16.2% to Rs 62.5 crore. The company has a return on equity of 16.9%, a debt to equity ratio of 0.54 and a market capitalisation of Rs 12,554 crore. The stock trades at a P/E of 43.2, below the industry P/E of 59.6.
Roadmap: The company adds hospitals in a cluster model, so each new site draws referrals from nearby facilities. Its focus on child and women’s healthcare is a defined niche where few organised competitors operate at scale, which helps both pricing and brand recall.
What to watch: Monitor how fast new clusters in Delhi NCR and other regions reach breakeven.
Why Metropolis Healthcare Features Among These Paediatric Care and Diagnostics Stocks
Among the children’s hospital shares on this list, Metropolis Healthcare, headquartered in Mumbai, is a pathology and diagnostics company that runs a national network of laboratories, patient service centres and collection points, and also serves hospitals and corporate clients.
In the June 2026 quarter, revenue grew 15.7% year on year to Rs 455 crore, while net profit rose 25.7% to Rs 56.9 crore. Revenue rose from Rs 1,246 crore in FY22 to Rs 1,671 crore in FY26, a compound annual growth rate of 7.6%.
Net profit grew from Rs 143 crore in FY23 to Rs 191 crore in FY26, which works out to a compound annual growth rate of 10.1%. The company has a return on equity of 12.6%, a debt to equity ratio of 0.15 and a market capitalisation of Rs 10,780 crore. The stock trades at a P/E of 53.1, below the industry P/E of 59.6.
Roadmap: The company is deepening its presence in existing regions while extending into new cities through collection points and partner labs. A larger share of specialised tests in oncology, genetics and wellness lifts revenue per patient and helps its mix.
What to watch: Follow test volumes per patient and the pace at which newer regions turn profitable.
Why Fortis Healthcare Features Among These Paediatric Care and Diagnostics Stocks
Among the three companies on this list, Fortis Healthcare operates a network of multi-specialty hospitals across India, with strengths in cardiac sciences, oncology, neurosciences and orthopaedics, and it also runs a diagnostics business.
The company has a return on equity of 10.5%, a debt to equity ratio of 0.35 and a market capitalisation of Rs 55,554 crore. The stock trades at a P/E of 51.9, below the industry P/E of 59.6.
Revenue rose from Rs 5,745 crore in FY22 to Rs 9,178 crore in FY26, a compound annual growth rate of 12.4%. Net profit grew from Rs 790 crore in FY22 to Rs 1,064 crore in FY26, which works out to a compound annual growth rate of 7.7%. In the June 2026 quarter, revenue grew 17.3% year on year to Rs 2,560 crore, while net profit rose 2.3% to Rs 273 crore.
Roadmap: The company is adding beds at existing hospitals and building new capacity in cities where demand for advanced care is rising. Its diagnostics arm and a growing share of complex procedures widen the earnings base beyond routine admissions.
What to watch: Track bed additions, occupancy and revenue per occupied bed.
Rainbow Children’s Medicare vs Metropolis Healthcare vs Fortis Healthcare on Key Financials
The table below sets the three paediatric care and diagnostics stocks side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Rainbow Children’s Medicare | 993 | 1,747 | 15.2% | 282 | 16.1% |
| Metropolis Healthcare | 1,246 | 1,671 | 7.6% | 191 | 11.4% |
| Fortis Healthcare | 5,745 | 9,178 | 12.4% | 1,064 | 11.6% |
Rainbow Children’s Medicare posts the highest return on equity in this group at 16.9%. Fortis Healthcare has the largest FY26 revenue at Rs 9,178 crore, and Rainbow Children’s Medicare shows the fastest revenue growth with a 15.2% compound annual rate. A useful habit with paediatric care and diagnostics stocks is to check each new quarterly result against the capacity plans the company described earlier. Many investors spread money across several pathology network stocks instead of one name, which keeps a single result from deciding the outcome.
The June 2026 quarter, the latest reported, gives a fresh read on momentum:
| Company | Q1 FY26 Revenue (Rs Cr) | Q1 FY27 Revenue (Rs Cr) | Year-on-Year Growth |
|---|---|---|---|
| Rainbow Children’s Medicare | 373 | 483 | 29.4% |
| Metropolis Healthcare | 394 | 455 | 15.7% |
| Fortis Healthcare | 2,182 | 2,560 | 17.3% |
Key Risks to Check Before Investing in Paediatric Care and Diagnostics Stocks
Every theme carries risks that deserve a check before any decision. For these paediatric care and diagnostics stocks, the main points are: Long-term children’s hospital shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.
- Ramp-up timing. New hospitals and labs take time to reach stable utilisation.
- Doctor availability. Specialist doctors are central to growth and hard to attract.
- Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter paediatric care and diagnostics stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Paediatric Care and Diagnostics Stocks
Paediatric care and diagnostics stocks reward investors who follow occupancy, test volumes and new capacity together. Rainbow Children’s Medicare, Metropolis Healthcare and Fortis Healthcare each have a clear expansion path. Based on the 21 October 2026 close, Rainbow Children’s Medicare trades at Rs 1,209, Metropolis Healthcare at Rs 533.6 and Fortis Healthcare at Rs 729. Valuation matters as much as growth, so compare each company’s P/E with its industry P/E before adding any of these paediatric care and diagnostics stocks to a watchlist.
Download the Univest iOS App or Univest Android App to track paediatric care and diagnostics stocks, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are paediatric care and diagnostics stocks?
Ans. Paediatric care and diagnostics stocks are listed companies that run hospitals and diagnostic laboratories on a commercial basis. Their earnings depend on bed capacity, occupancy, test volumes and the mix of services. This list looks at three of them, Rainbow Children’s Medicare, Metropolis Healthcare and Fortis Healthcare, using reported FY22 to FY26 financials and the 21 October 2026 closing prices.
Which paediatric care and diagnostics stocks are covered in this list?
Ans. This list covers Rainbow Children’s Medicare, Metropolis Healthcare and Fortis Healthcare. Based on the 21 October 2026 close, Rainbow Children’s Medicare traded at Rs 1,209, Metropolis Healthcare at Rs 533.6 and Fortis Healthcare at Rs 729. Their return on equity ranges from 10.5% to 16.9%, and their revenue compound annual growth from FY22 to FY26 ranges from 7.6% to 15.2%.
Why do paediatric care and diagnostics stocks have a strong future roadmap in India?
Ans. Paediatric care and diagnostics stocks have a strong roadmap in India because rising incomes, insurance cover and awareness of early testing and specialised care are growing faster than the supply of organised providers. The main drivers are as follows. Specialised care. Paediatric and maternity services draw repeat patients. Preventive testing. More people take regular health checks. Capacity additions. New beds and centres widen reach in proven cities. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Rainbow Children’s Medicare performed financially?
Ans. Revenue rose from Rs 993 crore in FY22 to Rs 1,747 crore in FY26, a compound annual growth rate of 15.2%. Net profit grew from Rs 139 crore in FY22 to Rs 282 crore in FY26, which works out to a compound annual growth rate of 19.4%. In the June 2026 quarter, revenue grew 29.4% year on year to Rs 483 crore, while net profit rose 16.2% to Rs 62.5 crore. The company has a return on equity of 16.9%, a debt to equity ratio of 0.54 and a market capitalisation of Rs 12,554 crore. The stock trades at a P/E of 43.2, below the industry P/E of 59.6. Looking ahead, the company adds hospitals in a cluster model, so each new site draws referrals from nearby facilities. Its focus on child and women’s healthcare is a defined niche where few organised competitors operate at scale, which helps both pricing and brand recall.
How has Metropolis Healthcare performed financially?
Ans. Revenue rose from Rs 1,246 crore in FY22 to Rs 1,671 crore in FY26, a compound annual growth rate of 7.6%. Net profit grew from Rs 143 crore in FY23 to Rs 191 crore in FY26, which works out to a compound annual growth rate of 10.1%. In the June 2026 quarter, revenue grew 15.7% year on year to Rs 455 crore, while net profit rose 25.7% to Rs 56.9 crore. The company has a return on equity of 12.6%, a debt to equity ratio of 0.15 and a market capitalisation of Rs 10,780 crore. The stock trades at a P/E of 53.1, below the industry P/E of 59.6. Looking ahead, the company is deepening its presence in existing regions while extending into new cities through collection points and partner labs. A larger share of specialised tests in oncology, genetics and wellness lifts revenue per patient and helps its mix.
How has Fortis Healthcare performed financially?
Ans. Revenue rose from Rs 5,745 crore in FY22 to Rs 9,178 crore in FY26, a compound annual growth rate of 12.4%. Net profit grew from Rs 790 crore in FY22 to Rs 1,064 crore in FY26, which works out to a compound annual growth rate of 7.7%. In the June 2026 quarter, revenue grew 17.3% year on year to Rs 2,560 crore, while net profit rose 2.3% to Rs 273 crore. The company has a return on equity of 10.5%, a debt to equity ratio of 0.35 and a market capitalisation of Rs 55,554 crore. The stock trades at a P/E of 51.9, below the industry P/E of 59.6. Looking ahead, the company is adding beds at existing hospitals and building new capacity in cities where demand for advanced care is rising. Its diagnostics arm and a growing share of complex procedures widen the earnings base beyond routine admissions.
What risks should investors check before buying paediatric care and diagnostics stocks?
Ans. Investors should check a few risks before buying paediatric care and diagnostics stocks. Ramp-up timing. New hospitals and labs take time to reach stable utilisation. Doctor availability. Specialist doctors are central to growth and hard to attract. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of paediatric care and diagnostics stocks investment advice?
Ans. No. This article is educational and uses publicly available data as of the 21 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.
